Influence of Vertical Implant Position on Marginal Bone Loss in Cases With Thin Phenotype (NCT07483086) | Clinical Trial Compass
RecruitingNot Applicable
Influence of Vertical Implant Position on Marginal Bone Loss in Cases With Thin Phenotype
Egypt30 participantsStarted 2025-01-16
Plain-language summary
The goal of this clinical trial is to learn if vertical position of the dental implant will affect the bone around the implant in place of a missing tooth that happens to be bounded by two natural teeth. It will also measure esthetics and patient satisfaction. The main questions it aims to answer are:
Does vertical implant position below the crest of the bone lead to less marginal bone loss? Will it affect implant survival as well as quality of soft tissue, esthetics and patient satisfaction?
Participants will:
Have an implant placed at the bone level or 2 mm below the bone level Visit the clinic once every 3 months for checkups, radiographs, and readings
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients with single missing upper anterior or premolar teeth
* Patients with minimum buccolingual width of 6 mm and mesiodistal width of 6 mm
* Patients with thin soft tissue phenotype
* Patients with healthy systemic conditions.
* Patients older than 18 years.
* Good oral hygiene.
* Cooperative patients who accept a one-year follow-up period.
* Patients who consent to being part of the study (sign an informed consent form).
* Adequate inter-arch space for implant placement.
* Favorable occlusion (no traumatic occlusion).
* Absence of allergy to the prescribed medications.
Exclusion Criteria:
* Patients with inadequate bone volume and/ or quality
* Patients with local root remnants
* Patients with inadequate wound healing
* Patients with signs of acute infection related to the area of interest.
* Patients with habits that may jeopardize the implant longevity and affect the results of the study such as parafunctional habits (Lobbezoo et al., 2006).
* Heavy smokers (more than 10 cigarettes per day) (Lambert, Morris and Ochi, 2000).
* Metabolic diseases such as diabetes or hyperthyroidism as well as systemic medications such as chemotherapy or bisphosphonates
* Pregnant or nursing women.
* Uncooperative patients.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Marginal bone loss (crestal bone loss)
Timeframe: Assessment at baseline, 3 months post-operative, 6 months post-operative, 9 months post-operative and 12 months post-operative